Please assess the completion status of the following clinical trial:

Trial Title: Fimasartan Achieving SBP Target (FAST) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who voluntarily signed informed consent for participating in this clinical trial~2. Male and female between 19 and 70 years old~3. Subjects whose mean sitting SBP(siSBP) of 3 measurements is above 140mmHg at visit 2 with mild to moderate essential hypertension (Subjects who have not taken anti-hypertensive drugs within 3 months should have mean siSBP above 140mmHg at visit 1)~4. Subject who can understand the trial procedures and be willing to cooperate the trial~Exclusion Criteria:~1. Severe hypertension patients with mean siSBP ≥ 180mmHg or siDBP ≥110mmHg at the assessment of Screening visit(Visit1) and Baseline visit (Visit2).~2. Patients whose difference between maximum and minimum among 3 times of blood pressure measurement is over 20mmHg(siSBP) or 10mmHg(siDBP) at visit1 and visit2.~3. Patients whose medication compliance is under 70% at visit 2.~4. Secondary hypertension patients, but not limited to the following diseases (example: renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc).~5. Patients who have postural hypotension with manifestation.~6. Subjects with severe insulin-dependent Diabetes Mellitus(DM) or uncontrolled DM(HbA1c \> 9% at screening visit, modified dosage of an oral hypoglycemic agent within 12 weeks prior to screening visit, or currently use of active insulin treatment).~7. History of malignant tumor including leukemia and lymphoma in the past 5 years.~8. Subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy, past or current medical history with wasting disease, autoimmune diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus) or connective tissue disease.~9. Medical history with hypersensitivity to angiotensin II antagonist.~10. Clinically significant renal and liver disorders such as dialysis, cirrhosis, biliary obstruction, cholestasis and liver failure. Patients who have below abnormality in the laboratory results at screening visit.~    * Creatinine clearance(Cockroft-Gault)\<30mL/min~   * ALT, AST ≥ 2 times upper normal limit~   * Clinically significant hypokalemia(K\<3.5mmol/L) or hyperkalemia(K\>5.5mmol/L)~11. Subjects have history of any of the followings within the past 6 months or determined clinically significant by investigators.~    * Severe heart disease (Heart failure New York Heart Association(NYHA) class 3 and 4), ischemic heart disease (angina pectoris, myocardial infarction), peripheral vascular disease, percutaneous transluminal coronary angioplasty or coronary artery bypass graft.~   * Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve stenosis, or mitral valve stenosis.~   * Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or any other clinical significant arrhythmia.~   * Severe cerebrovascular disorder(e.g.stroke, cerebral infarction or cerebral hemorrhage)~12. Subjects with known moderate or malignant retinosis in the past 6 months (e.g. retinal hemorrhage, visual disturbance or retinal microaneurysm)~13. Subjects with history of abusing drugs or alcohol within the past 2 years.~14. Pregnant women or lactating female.~15. Subjects with following surgical and internal disease that may affect absorption, distribution, metabolism or excretion of drugs and have conditions which include the following (but are not limited to): history of major gastrointestinal surgeries including gastrectomy, gastro-enterostomy or bowel resection, gastrointestinal bypass graft and stabling; current active gastritis, gastrointestinal and rectal bleeding, presence of active inflammatory bowel syndrome within the past 12 months.~16. Subjects with shock, depletion of body fluid or sodium ion not able to correct.~17. Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.~18. Medical history with clinically significant hypersensitivity to any components or other drugs on the investigational product or additives(yellow4 and yellow 5).~19. Subjects planning pregnancy or childbearing potential who are not using effective contraceptive methods.~20. Subjects who are participating in another trial or took other investigational product within 12 weeks prior to screening visit.~21. Subjects with other reasons not specified above and ineligible to participate in this clinical trial at discretion of study investigators.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fimasartan (Type: EXPERIMENTAL): Placebo daily for 2 weeks and Fimasartan 60mg daily for 2 weeks and 120mg daily for 4 weeks
- Valsartan (Type: ACTIVE_COMPARATOR): Placebo daily for 2 weeks and Valsartan 80mg daily for 2 weeks and 160mg daily for 4 weeks
- Olmesartan medoxomil (Type: OTHER): Reference group. Placebo daily for 2 weeks and Olmesartan 10mg daily for 2 weeks and 20mg daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).